Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Martin Whyte, Associate Professor of Metabolic Medicine, University of Surrey

Wegovy: more people may soon be eligible to access weight-loss drug under new pilot scheme

Wegovy has the same active ingredient as Ozempic. myskin/ Shutterstock

One in four adults in the UK are obese. Obesity is associated with many health conditions including high blood pressure, type 2 diabetes, heart attacks, stroke and cancer. The financial cost of obesity to the NHS is an estimated £6 billion a year.

In an effort to reduce the burden of obesity on the NHS and cut waiting times, the UK government has announced a £40 million pilot scheme that will explore ways of making the obesity drug Wegovy available to many more patients living in the UK.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.